



PSOMAGEN



GUTBIOME<sup>+</sup>

Name: **Nicholas Perry**

Kit ID: **BBH9671**

Test Date: **10/15/2021**

# Psomagen GutBiome<sup>+</sup>

## Result Report



powered by  
**MICROBA**





PSOMAGEN




GUTBIOME<sup>+</sup>

# Your Gut Microbiome Result Report

This is a comprehensive report, detailing key information about your personal gut microbiome by whole shotgun metagenome sequencing. As new information about the links between the gut microbiome and health are revealed, we will continue to update your online report to include these new findings.

Any information provided by us (including any information contained on our website or in any microbiome report) is for information purposes only. Such information is not medical advice and must not be taken to be a substitute for a consultation with your health care professional or doctor. It is not intended to diagnose condition nor prescribe the use of any remedy, diet or lifestyle practices. Your health is your responsibility and if you have any concerns related to your health, we recommended that you seek the advice of your health care practitioner or doctor.

If you are a health care practitioner and would like to learn more about this informational report, please contact us at [help@psomagen.com](mailto:help@psomagen.com).







# Result Report Contents

---

## Intro

|                                                                      |    |
|----------------------------------------------------------------------|----|
| • Introduction to Microbiome and Taxonomy                            | 05 |
| • History of the Human Microbiome                                    | 06 |
| • The Gut Microbiome and the Analysis Method                         | 07 |
| • What is the Difference between<br>GutBiome and GutBiome+ Services? | 08 |

---

## Test Results

|                                   |    |
|-----------------------------------|----|
| • Gut Health Score                | 11 |
| • Beneficial vs. Harmful Bacteria | 12 |
| • Probiotics Profile              | 13 |
| • Your Gut Type                   | 15 |
| • Lifestyle Status                | 18 |
| • Nutrition Utility               | 20 |
| • Metabolic Supply                | 22 |
| • Metabolic Concern               | 25 |
| • Microbial Diversity             | 27 |
| • Microbe Profile                 | 28 |




PSOMAGEN



GUTBIOME<sup>+</sup>

# Intro


- 
- Introduction to Microbiome and Taxonomy
  - History of the Human Microbiome
  - The Gut Microbiome and the Analysis Method
  - What is the Difference between GutBiome and GutBiome<sup>+</sup> Services?





# Introduction to Microbiome and Taxonomy

All living things, including animals, insects, plants, and marine organisms, are closely related to microorganisms. You can't see these microorganisms, but **they are always present in aerosols, water and food, on the desk and bed, etc. In addition, they are colonized in the human body such as the skin, mammary glands, lungs, biliary tract, oral mucosa, saliva, vagina, and gastrointestinal tract (GIT)** (Gupta *et al.*, 2017). They form their own ecosystems, or communities, to adapt to the environment of these different habitats. The genomes of microbial community are called the microbiome and are classified according to each habitat such as gut microbiome, skin microbiome, oral microbiome, etc.



This report provides information on important microorganisms, their metabolites, and pathways in a human body. The taxonomy information shows the scientific classification of all living organisms into hierarchical groups based on their characteristics or evolutionary relatedness. **Bacterial taxonomy** uses the following levels in ascending order: **strain, species, genus, family, order, class, phylum, and domain.**






# History of the Human Microbiome

The **Human Genome Project (HGP)**, the world's largest collaborative biological project, officially launched in 1990 and was completed in 2003 (Zwart, 2015). The human genome consists of about 23,000 genes, whereas the microbiome encodes over 3 million genes (Valdes *et al.*, 2018). The microorganisms that live inside and on the human body are estimated to be 10 times more than human somatic and germ cells (Turnbaugh *et al.*, 2007).

With the development of DNA sequencing technologies, the **Human Microbiome Project (HMP)** was also launched by the National Institute of Health (NIH) and received \$215 million from 2007 to 2016 (NIH Human Microbiome Portfolio Analysis Team, 2019). The HMP is explained by 'a logical conceptual and experimental extension of the Human Genome Project' (Turnbaugh *et al.*, 2007). The HMP program, organized into two phases (HMP1 and HMP2), focused on identifying human microbial flora (HMP1) and investigating their role in human health and disease states (HMP2) (Proctor *et al.*, 2019). By the end of 2017, HMP investigators published over 650 scientific papers that had been cited over 70,000 times (NIH, <https://commonfund.nih.gov/hmp>).



# The Gut Microbiome and the Analysis Method

In the human GIT, there are about 100 trillion microorganisms and consists of bacteria, viruses, fungi, and protozoa (Valdes *et al.*, 2018). The gut microbiome plays an important role in the absorption of macronutrients (carbohydrates, proteins, and fats) and micronutrients (vitamins and minerals), and production of enzymes, vitamins, amino acids, and short chain fatty acids (SCFAs). The gut microbiome and their metabolites determine the differential modulation of the innate and adaptive immunity (Kinross *et al.*, 2011). Therefore, the gut microbiome is important for human health and disease. The gut microbiome and their metabolites influence weight gain/loss and mediate human mental, neurodegenerative, and neurodevelopment (Lin *et al.*, 2012) (Sarkar *et al.*, 2016).

This report provides accurate information about the microbiome composition and bacterial genetic characteristics by **whole metagenomics analysis** from stool sample. Whole metagenomics analysis can confirm the identification and quantification of significant bacterial genes through shotgun metagenomics sequencing. The scores are calculated as relative values for the Psomagen cohort and provided as a result.

# What is the Difference between GutBiome and GutBiome<sup>+</sup> Services?

The high-throughput sequencing technology, including 16s rRNA gene or whole metagenome shotgun sequencing, enabled the analysis of very complex samples. The 'Whole Metagenome Shotgun Sequencing' has allowed the genomic analysis and quantification of expression levels of active bacterial gene functions in your gut (Escobar-Zepeda *et al.*, 2018).

|                          | GutBiome                                                                              | GutBiome <sup>+</sup>                                                                                       |
|--------------------------|---------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| Sample                   | Stool                                                                                 | Stool                                                                                                       |
| Target sequencing region | · Bacterial 16s rRNA sequences                                                        | Whole DNA sequences<br>(Also including Human DNA, Archaea, Eukaryote, etc.)                                 |
| Platform                 | · Illumina MiSeq                                                                      | · Illumina NovaSeq                                                                                          |
| Resolution               | · Low<br>· Screening and identification of intestinal bacteria                        | · High<br>· Identification and quantification of whole genes in the gut                                     |
| Gene/functional analysis | · Assumptions based on known references<br>· Does not measure bacterial gene function | · Novel gene detection<br>· Exact estimation of genes and functions                                         |
| Plasmids/Phages/Viruses  | · Not detectable                                                                      | · A certain level detectable                                                                                |
| Computational tools      | · Many well developed tool available                                                  | · High variation of tools available or under development                                                    |
| Host contamination       | · Applicable to high host DNA contamination                                           | · Not only classifiable but also usable as content                                                          |
| Contributors             | · Only identified bacteria                                                            | · Host DNA, Archaea, Eukaryote, etc.<br>· Number of bacterial genes and functions; metabolites and pathways |



## What is the Difference between GutBiome and GutBiome<sup>+</sup> Services?

|                                | GutBiome  | GutBiome <sup>+</sup> |
|--------------------------------|-----------|-----------------------|
| NGS Reads                      | < 100,000 | > 7,000,000           |
| Probiotics Profile             | ✓         | ✓                     |
| Lifestyle Status               | ✓         | ✓                     |
| Nutrition Utility              | ✓         | ✓                     |
| Metabolism                     | ✓         | ✓                     |
| Microbe Profile                | -         | ✓                     |
| Sample Composition             | -         | ✓                     |
| Completed Microbiome Profile   | -         | ✓                     |
| Food / Prebiotics Suggestion   | -         | ✓                     |
| Major Metabolites              | -         | ✓                     |
| Nutrition / Lifestyle Solution | -         | ✓                     |
| Percentage of Novel Microbes   | -         | ✓                     |




# Test Results

---

- Gut Health Score
- Beneficial vs. Harmful Bacteria
- Probiotics Profile
- Your Gut Type
- Lifestyle Status
- Nutrition Utility
- Metabolic Supply
- Metabolic Concern
- Microbial Diversity
- Microbe Profile

# Gut Health Score

This score is an indication of your overall gut health, based on our categories listed below. They are key indicators of gut health, and their contributions to the “Gut Health Score” are weighted based on the scientific evidence that shows the level of influence each one has shown to have on our health. The healthy comparison range for the “Gut Health Score” is **34 ~ 63**



## Gut Health Score Contributors

| List                  | Range   | You  | List                         | Range   | You  |
|-----------------------|---------|------|------------------------------|---------|------|
| Butyrate Production   | 12 ~ 26 | 16.5 | Hexa-acylated LPS Production | 0 ~ 1   | 0    |
| Propionate Production | 25 ~ 52 | 58.1 | Trimethylamine Production    | 0 ~ 0.1 | 0    |
| Acetate Production    | 58 ~ 75 | 74.2 | Protein Degradation          | 63 ~ 77 | 77.7 |
| Fiber Degradation     | 61 ~ 76 | 74.2 | Human DNA                    | 0 ~ 2   | 0    |
| Microbial Diversity   | 60 ~ 81 | 46.8 |                              |         |      |
| IPA Production        | 0 ~ 2   | 2.5  |                              |         |      |

■ Potential to **promote** your health

■ Potential to **reduce** your health



# Probiotics Profile

Here are 16 probiotics that have been recognized for their functions in the gut. They are beneficial for your health if adequate amounts are present in the enteric system, there is a strong possibility that they exist in smaller amounts compared to other gut microbes.

Check which probiotics are currently lacking in your system.

| Probiotics Category    |                    | Result       | Major Characteristics                                                                                 |
|------------------------|--------------------|--------------|-------------------------------------------------------------------------------------------------------|
| <i>Bifidobacterium</i> | <i>animalis</i>    | Not detected | Improve bowel movement, reduce eczema, relieve diarrhea                                               |
|                        | <i>bifidum</i>     | Not detected | Synthesize vitamin group B, prevent acute diarrhea, reduce infection from <i>E. coli</i>              |
|                        | <i>breve</i>       | Not detected | Inhibit <i>Helicobacter</i> sp., prevent gastric ulcer, enhance immunity, protect from liver toxicity |
|                        | <i>longum</i>      | Not detected | Lower cholesterol, improve atopy, reduce inflammation in the colon                                    |
| <i>Lactobacillus</i>   | <i>acidophilus</i> | Not detected | Gut regulation, anti-cancer effect, lower cholesterol level, synthesize vitamin group B               |
|                        | <i>casei</i>       | Not detected | Produce carbohydrate-degrading amylase, improve lactose intolerance, digestive functions              |
|                        | <i>fermentum</i>   | Not detected | Lower blood sugar, anti-oxidation, inhibit production of lipoperoxide, lower cholesterol              |
|                        | <i>gasseri</i>     | Not detected | Secrete cholesterol lowering factors, inhibit microbes that induce enteric diseases, immunomodulation |
|                        | <i>helveticus</i>  | Not detected | Prevent arthritis, prevent dementia, decrease opportunistic pathogens                                 |
|                        | <i>paracasei</i>   | Not detected | Adsorb cholesterol, inhibit growth of pathogens, control allergic reactions                           |
|                        | <i>plantarum</i>   | Not detected | Prevent and improve genitourinary infections, improve lactose intolerance                             |
|                        | <i>reuteri</i>     | Not detected | Excellent amylolysis activities, defense against pathogens, improve vaginal candidiasis               |

| Probiotics Category  |                     | Result       | Major Characteristics                                                       |
|----------------------|---------------------|--------------|-----------------------------------------------------------------------------|
| <i>Lactobacillus</i> | <i>rhannosus</i>    | Not detected | Improve vaginal candidiasis, improve atopy, inhibit <i>Helicobacter</i> sp. |
|                      | <i>salivarius</i>   | Not detected | Enhance immunity, eliminate halitosis, inhibit <i>Salmonella</i> sp.        |
| <i>Lactococcus</i>   | <i>lactis</i>       | Not detected | Stability against live bacteria, inhibit growth of pathogens                |
| <i>Streptococcus</i> | <i>thermophilus</i> | Not detected | Improve lactose intolerance, enhance immunity                               |

## How to Utilize Your Results



As the gut microbiome environment differs among people, it is hard to expect the same effect from one product for everyone. Check the probiotic strains your system lack and find the right probiotics product for you.



Just like regular health check-ups, the constant monitoring of your gut environment and the supplementation of insufficient probiotics make managing your health easier.



People with recent history of gastrointestinal surgery, gastrointestinal bleeding or perforation, and/or patients with immune system abnormalities may experience side effects from ingestion of probiotics. Therefore, consulting with a board-certified doctor is highly recommended before consumption of supplements.

# Your Gut Type

Even gut microbes have their favorite foods. Therefore, the distribution of your gut microbial environment is influenced by your eating habits. The enteric, or gut, system can be largely categorized into three types regardless of age or gender.

Check your gut type to review eating habits and learn what food you should eat to improve it!

Type1. *Bacteroides* type

## PROTEIN - FAVORITE

This type is usually found in those who mainly eat meat as their source of proteins, fats, and carbohydrates.

**6.6 %**

Type2. *Prevotella* type

## FIBER - FAVORITE

This type is usually found in those who mainly eat vegetables with dietary fibers.

**40.2 %**

Type3. *Ruminococcaceae* type

## OMNIVOROUS

Similar to type1, but this type can absorb carbohydrates very easily and it's most likely to gain weight easily.


**7 %**

## Type 2 *Prevotella* type

# FIBER - FAVORITE

If you are Type 2 *Prevotella*, it is very possible that you eat more dietary fiber with a vegetable diet and less meat. *Prevotella* helps synthesize thiamine, a vital vitamin, leading to a relatively low chance of discomfort caused by chronic fatigue or poor concentration.

However, the *Prevotella* type who has a high chance of stomachache, should be careful about daily food intake and comply with the following recommendations.



|                        | You    | Average |
|------------------------|--------|---------|
| <i>Bacteroides</i>     | 6.6 %  | 12.2 %  |
| <i>Prevotella</i>      | 40.2 % | 6 %     |
| <i>Ruminococcaceae</i> | 7 %    | 9.5 %   |



# Your Gut Type Solution



---

## Maintain a balanced diet with the three main nutrients

Do you usually eat a balanced diet with carbohydrates, fats, and proteins?

If not, why don't you eat a variety of food from now on?

---

## Get essential fatty acids

Omega-3 and omega-6 are essential fatty acids that our body cannot synthesize and must be ingested from a diet. They can be ingested from tuna, mackerel, nuts, and perilla seed oil.

---

## Get essential amino acids

Eight of the amino acids, the building blocks of proteins, cannot be synthesized in our body and must be ingested from a diet. They can be ingested from meat.







# Your Sub Gut Type

**Type 1** *Bacteroides* type

## PROTEIN - FAVORITE



As a Type 1 *Bacteroides*, it is highly possible that you have mainly eaten meat as your source of protein and fat, and ate fewer vegetables. But the *Bacteroides* type can easily produce biotin, which aids in energy metabolism, and if the following recommendations are met, you can maintain a healthy body.

### Eat a plate of vegetables a day

When eating meat, try to accompany it with a salad. How about eating some cucumbers, carrots, or broccoli with your favorite dip as a healthy snack option?

### Control intake ratio

If you are eating in the order of meat > grains > vegetables, changing the order to vegetables > meat > grains This not only helps to control calories, but also to maintain healthy eating habits.

### Reduce calorie intake

Having meat-centric meals can easily make you take in many more calories than average. Try reducing the amount of meat by 1/3 of what you normally eat.

**Type 3** *Ruminococcaceae* type

## OMNIVOROUS



If you are a Type 3 *Ruminococcaceae*, it is very possible that you eat more carbohydrates such as rice, bread, and fewer vegetables. *Ruminococcaceae* helps absorb carbohydrates and convert them to fats, leading to a high risk of obesity. However, the *Ruminococcaceae* type can get better with a change of eating habits. If you follow the recommendations below, you can stay healthy.

### Control your carbohydrate intake

Since you are eating more carbohydrates than other nutrients, try lowering the intake. Abstaining from fruits and snacks after meals will also help.

### Control the types of carbohydrates

Processed food such as soup and bread rapidly raise the blood sugar level, causing obesity and various metabolic disorders. Reduce processed food intake a little bit.

### Eat dietary fiber

Eating multi-grain and various vegetables that are rich in dietary fiber enables you to kill two birds with one stone. There is an increase in dietary fiber intake with satiation and a decrease in carbohydrates intake.



# Lifestyle Status

The knowledge that the gut microbes influence our health has transformed into significant lifestyle pursuits. Links between the central nervous system and the gut microbes may contribute to conditions such as depression and fatigue. The microbiome-gut-brain axis also regulates your sleep and appetites.

This score reflects the functionality of your gut microbial system. It would promote an optimal balance and influence of probiotics and beneficial, commensal and pathogenic bacteria in your lifestyle and mental health.

A high score indicates good balance of microbes in your system.



## Total Score

# 74

The "healthy" comparison range for the "Lifestyle Status Score" is **33 ~ 67**

## Behavior

Gut microbes play a role in regulating the function of the brain, nervous system, and mental health.

| List                  | Range   | You  |
|-----------------------|---------|------|
| GABA Production       | 8 ~ 33  | 13.7 |
| IPA Production        | 0 ~ 2   | 2.5  |
| Vitamin B9 Production | 34 ~ 58 | 57.9 |

## Fatigue

Fatigue and tiredness are symptoms of many body system disorders.

A disturbed gut microbiota and decrease of pH by abnormally enriched lactic acid bacteria may lead to elevate levels of fatigue.

| List                     | Range   | You  |
|--------------------------|---------|------|
| D-Lactic acid Production | 22 ~ 49 | 14.3 |

# Lifestyle Status

## Sleep

Gut microbes can help you get a good night's sleep by generating GABA or by generating some metabolites that promote the serotonin production of your body.

| List                  | Range   | You  |
|-----------------------|---------|------|
| Butyrate Production   | 12 ~ 26 | 16.5 |
| GABA Production       | 8 ~ 33  | 13.7 |
| Propionate Production | 25 ~ 52 | 58.1 |

## Healthy Weight

Some microorganisms affect your weight by producing metabolites that help control your appetite or by affecting your calorie harvest.

| List                  | Range   | You  |
|-----------------------|---------|------|
| Butyrate Production   | 12 ~ 26 | 16.5 |
| Propionate Production | 25 ~ 52 | 58.1 |
| Methane Production    | 0 ~ 0.2 | 0    |

## Nutrition Utility

After you eat a meal, food gets broken down in your stomach and travels to your small intestine, where most nutrients are absorbed. The food components that cannot be absorbed in the small intestine, such as fiber and excess protein, make their way to your intestine where your gut microbiota break down these components into small molecules that are used by the host and other gut microbes. This score reflects your gut microbial functions that contain multiple activities related to digestion, as well as specific macronutrient break down ability. A high score indicates that the activities supporting the digestion system are high in your microbiome.



The "healthy" comparison range for the "Nutrition Utility Score" is 20 ~ 68

## Fiber Break Down

In comparison to the "healthy" group, it is considered beneficial when a similar or higher proportion of species that can break down fiber is detected. Fiber-consuming bacteria are responsible for producing important by-products like short chain fatty acids, which play a critical role in keeping the gut health. Prebiotic fibers can promote the growth of beneficial bacteria.

| List              | Range   | You  |
|-------------------|---------|------|
| Fiber Degradation | 61 ~ 76 | 74.2 |

## Protein Break Down

Most protein is absorbed by your body, however excess protein will pass on to the intestine, where it is available to the gut microbiome. Microorganisms that break down these proteins produce a variety of compounds, including some compounds that promote inflammation. If there is a high proportion of species that break down protein in the microbiome, make sure there is sufficient fiber in the diet and consider avoiding excessive consumption of protein.

| List                | Range   | You  |
|---------------------|---------|------|
| Protein Degradation | 63 ~ 77 | 77.7 |



# Nutrition Utility

## Starch Break Down

Low digestible carbohydrates including xylo-oligosaccharides (XOS), galacto-oligosaccharides (GOS) and fructans, inulin and fructo-oligosaccharides (FOS) are considered prebiotics factors. Some bacteria in the intestine can digest these carbohydrates and provide beneficial effects to human as a symbiotic relationship.

| List               | Range   | You  |
|--------------------|---------|------|
| Starch Degradation | 61 ~ 76 | 74.2 |

## Alcohol Metabolism

Excessive drinking has harmful effects on health by increasing the risk of many conditions involving varied organs and/or systems. Gut microbiota has been involved in the alcohol-related conditions and the prevention of these conditions. Several genes related to alcohol degradation in the gut microbiota are used as markers for alcohol metabolism utility.

| List                     | Range   | You |
|--------------------------|---------|-----|
| Alcohol Degradation      | 8 ~ 21  | 2.4 |
| Formaldehyde Degradation | 51 ~ 70 | 72  |

## Oxalate Consumption

Calcium oxalate is related with kidney stone. People who suffer from recurring, unexplained kidney stones have been observed to have a reduced level of genes for oxalate degradation in their microbiome compared to healthy people.

| List                | Range  | You |
|---------------------|--------|-----|
| Oxalate Consumption | 6 ~ 19 | 6.8 |

# Metabolic Supply

The gut microbiome is a key producer of some essential nutrients such as minerals, vitamins, and short chain fatty acids (SCFAs). These essential nutrients could be an energy source to the intestinal epithelial cells and affect the human metabolism. Additionally, a number of micronutrients are known to serve as antioxidants. This score indicates your gut microbial functions that lead to the production of nutrients known to beneficially affect many wellness areas.

A high score means specific metabolizing activities are high in your microbiome.



The "healthy" comparison range for the "Metabolic Supply Score" is 23 ~ 67

## GABA & IPA Production

Gut microbes produce (and consume) some important signaling molecules (called neurotransmitters) such as γ-aminobutyric acid (GABA), and indolepropionic acid (IPA). GABA & IPA influence your brain and regulate mood, appetite, and sleep.

| List            | Range  | You  |
|-----------------|--------|------|
| GABA Production | 8 ~ 33 | 13.7 |
| IPA Production  | 0 ~ 2  | 2.5  |

## Butyrate Production

Butyrate is a short chain fatty acid and is the main fuel source for gut cells, helps keep the gut cell barrier intact, can reduce inflammation, helps control appetite, and stimulates the production of serotonin from gut cells.

| List                | Range   | You  |
|---------------------|---------|------|
| Butyrate Production | 12 ~ 26 | 16.5 |

# Metabolic Supply

## Lactate Production

Lactate can reduce inflammation and helps keep the gut cell barrier intact. Some microbes can also convert lactate to the beneficial short chain fatty acids: acetate, propionate, and butyrate.

| List               | Range   | You  |
|--------------------|---------|------|
| Lactate Production | 29 ~ 62 | 22.5 |

## Propionate Production

Propionate helps maintain blood glucose levels, can reduce inflammation, helps control appetite and can stimulate the production of serotonin.

| List                  | Range   | You  |
|-----------------------|---------|------|
| Propionate Production | 25 ~ 52 | 58.1 |

## Vitamin Production

Vitamins are essential micronutrients and have biological effects on health by reducing the risk of infectious, inflammatory, and allergic response. For the prevention of vitamin deficiency, vitamins need to be provided sufficiently from diet, as well as gut microbiota.

| List                   | Range   | You  |
|------------------------|---------|------|
| Vitamin B2 Production  | 29 ~ 58 | 62.3 |
| Vitamin B7 Production  | 22 ~ 51 | 21   |
| Vitamin B9 Production  | 34 ~ 58 | 57.9 |
| Vitamin B12 Production | 18 ~ 48 | 22.9 |
| Vitamin K Production   | 1 ~ 9   | 4.8  |

# Metabolic Supply

## Branched Chain Amino Acids Production

Branched chain amino acids (BCAAs) are building blocks for muscles. They are involved in the regulation of glucose and fat metabolism, and are involved in the regulation of the immune system.

| List             | Range   | You  |
|------------------|---------|------|
| IPA Production   | 0 ~ 2   | 2.5  |
| BCAAs Production | 42 ~ 70 | 66.7 |




# Metabolic Concern

Gut microbe and the immune system are constantly shaping each other in a mutual aim to: keep away from various harmless substances, make our body tolerate food molecules, recognize invaders, and protect against pathogens in the intestine.

This score represents your gut microbial function that stimulate unnecessary immune response by producing non-beneficial metabolites or using up beneficial metabolites.

A high score means beneficial/non-beneficial metabolites balance is unstable by dysbiosis.



The "healthy" comparison range for the "Metabolic Concern Score" is 41 ~ 69

## Inflammation

Some microbial metabolites promote inflammatory response. The excessive inflammatory responses could introduce health issues.

| List                         | Range   | You  |
|------------------------------|---------|------|
| Acetate Production           | 58 ~ 75 | 74.2 |
| Butyrate Production          | 12 ~ 26 | 16.5 |
| Lactate Production           | 29 ~ 62 | 22.5 |
| Propionate Production        | 25 ~ 52 | 58.1 |
| Vitamin B9 Production        | 34 ~ 58 | 57.9 |
| Ammonia Production           | 2 ~ 9   | 0.7  |
| Histamine Production         | 0 ~ 1   | 0.2  |
| Human DNA                    | 0 ~ 2   | 0    |
| Hexa-acylated LPS Production | 0 ~ 1   | 0    |
| Protein Degradation          | 63 ~ 77 | 77.7 |

# Metabolic Concern

## Gas

As the microbes in your gut digest the fiber and the excess protein you consume, they produce different types of gases as a by-product. Flatulence is primarily made up of odorless gases such as nitrogen, hydrogen, carbon dioxide, and methane. A small percent of flatulence is made up of the gas hydrogen sulfide, which gives flatulence the characteristic rotten eggs smell.

| List                         | Range   | You |
|------------------------------|---------|-----|
| Ammonia Production           | 2 ~ 9   | 0.7 |
| Hydrogen Sulphide Production | 1 ~ 6   | 3.4 |
| Methane Production           | 0 ~ 0.2 | 0   |

## TMAO Production

Even though the role of Trimethylamine N-oxide (TMAO) is still unclear, increased TMAO levels have been observed in individuals with certain health issues.

| List                       | Range   | You |
|----------------------------|---------|-----|
| Trimethylamine Consumption | 0 ~ 0.3 | 0.1 |
| Trimethylamine Production  | 0 ~ 0.1 | 0   |

## GABA Consumption

γ-Aminobutyric acid (GABA) is an important neurotransmitter that can reduce feelings of anxiety and depression. In addition to producing GABA, gut microbiota can also consume GABA. The balance of production and consumption of GABA by gut microbes is an active area of research.


| List             | Range | You |
|------------------|-------|-----|
| GABA Consumption | 1 ~ 5 | 0.4 |

 Potential to **promote** your health

 Potential to **reduce** your health

# Microbial Diversity

Microbial diversity is a measure of both the different types and the amount of bacterial species in your samples. A varied diet rich in plant-based foods, such as fruits, vegetables, whole grains and nuts, is associated with increased microbial diversity. Low microbial diversity is often associated with poor health.




## Sample Composition

Most of the DNA in your stool (~99%) is from the microorganisms in your gut and only a small amount (~1%) is from you, the host.

The microorganisms in your gut fall into four main groups: bacteria, archaea (another form of microscopic life), eukaryotes (this includes fungi and parasites), and viruses. Below, we show the levels of bacteria, archaea, eukaryotes, and novel (unidentifiable) DNA in your sample.

The amount of human DNA in your sample is also shown. A high amount (greater than 4%) of human DNA may indicate gut inflammation. If you have greater than 4% of human DNA, and you did not accidentally touch your swab during sample collection, you should consult with a health care provider.



| List      | Range     | You  | Level   |
|-----------|-----------|------|---------|
| Bacteria  | 64.1~77.7 | 77.7 | HIGH    |
| Archaea   | 0.0~0.2   | 0.0  | AVERAGE |
| Eukaryote | 0.0~0.0   | 0.0  | AVERAGE |
| Human DNA | 0.0~1.7   | 0.0  | LOW     |
| Novel     | 22.3~35.8 | 22.3 | LOW     |

# Microbe Profile

## Complete Microbiome Profile

Below is a list of each species detected in your microbiome, in order of abundance. Some microbes have been associated with health outcomes in scientific studies, while little is known about some others.

Everybody's microbiome composition is different and science tells us that the functional capacity of the microbiome is more important than which species inhabit it.

| Phylum           | Species                             | Range      | You    | Level   |
|------------------|-------------------------------------|------------|--------|---------|
| Ascomycota       | <i>Candida albicans</i>             | 0 ~ 0.0 %  | 0.0 %  | AVERAGE |
| Ascomycota       | <i>Galactomyces candidus</i>        | 0 ~ 0.0 %  | 0.0 %  | AVERAGE |
| Ascomycota       | <i>Saccharomyces cerevisiae</i>     | 0 ~ 0.0 %  | 0.0 %  | AVERAGE |
| Bacteroidetes    | <i>Alistipes finegoldii</i>         | 0 ~ 1.0 %  | 0.8 %  | AVERAGE |
| Bacteroidetes    | <i>Alistipes obesi</i>              | 0 ~ 0.9 %  | 0.3 %  | AVERAGE |
| Bacteroidetes    | <i>Alistipes onderdonkii</i>        | 0 ~ 1.7 %  | 0.4 %  | AVERAGE |
| Bacteroidetes    | <i>Alistipes putredinis</i>         | 0 ~ 4.4 %  | 2.9 %  | AVERAGE |
| Bacteroidetes    | <i>Alistipes shahii</i>             | 0 ~ 1.7 %  | 0.3 %  | AVERAGE |
| Bacteroidetes    | <i>Alistipes_A ihumii</i>           | 0 ~ 0.2 %  | 0.1 %  | AVERAGE |
| Bacteroidetes    | <i>Bacteroides caccae</i>           | 0 ~ 0.9 %  | 0.6 %  | AVERAGE |
| Bacteroidetes    | <i>Bacteroides cellulosilyticus</i> | 0 ~ 1.8 %  | 0.2 %  | AVERAGE |
| Bacteroidetes    | <i>Bacteroides faecis</i>           | 0 ~ 0.4 %  | 0.1 %  | AVERAGE |
| Bacteroidetes    | <i>Bacteroides salyersiae</i>       | 0 ~ 0.2 %  | 0.2 %  | HIGH    |
| Bacteroidetes    | <i>Bacteroides uniformis</i>        | 0 ~ 7.7 %  | 2.3 %  | AVERAGE |
| Bacteroidetes    | <i>Bacteroides_B vulgatus</i>       | 0 ~ 4.9 %  | 3.2 %  | AVERAGE |
| Bacteroidetes    | <i>Butyrivimonas virosa</i>         | 0 ~ 0.1 %  | 0.5 %  | HIGH    |
| Bacteroidetes    | <i>Parabacteroides distasonis</i>   | 0 ~ 1.1 %  | 1.1 %  | HIGH    |
| Bacteroidetes    | <i>Parabacteroides merdae</i>       | 0 ~ 0.9 %  | 1.2 %  | HIGH    |
| Bacteroidetes    | <i>Prevotella copri</i>             | 0 ~ 20.7 % | 38.9 % | HIGH    |
| Bacteroidetes    | <i>Prevotella stercorea</i>         | 0 ~ 0.0 %  | 1.3 %  | HIGH    |
| Bacteroidetes    | <i>UBA6382 sp</i>                   | 0 ~ 0.0 %  | 0.4 %  | HIGH    |
| Blastocystis     | <i>Blastocystis sp. DMP/02-328</i>  | 0 ~ 0.0 %  | 0.0 %  | AVERAGE |
| Blastocystis     | <i>Blastocystis sp. subtype 1</i>   | 0 ~ 0.0 %  | 0.0 %  | AVERAGE |
| Blastocystis     | <i>Blastocystis sp. subtype 3</i>   | 0 ~ 0.0 %  | 0.0 %  | AVERAGE |
| Blastocystis     | <i>Blastocystis sp. subtype 4</i>   | 0 ~ 0.0 %  | 0.0 %  | AVERAGE |
| Desulfobacterota | <i>Bilophila wadsworthia</i>        | 0 ~ 0.3 %  | 0.1 %  | AVERAGE |
| Desulfobacterota | <i>Desulfovibrio piger</i>          | 0 ~ 0.3 %  | 0.3 %  | AVERAGE |
| Firmicutes       | <i>Catenibacterium mitsuokai</i>    | 0 ~ 0.0 %  | 0.1 %  | HIGH    |
| Firmicutes_A     | <i>Agathobacter faecis</i>          | 0 ~ 1.9 %  | 0.9 %  | AVERAGE |
| Firmicutes_A     | <i>Anaerotignum sp1</i>             | 0 ~ 0.2 %  | 0.2 %  | HIGH    |

# Microbe Profile

## Complete Microbiome Profile

Below is a list of each species detected in your microbiome, in order of abundance. Some microbes have been associated with health outcomes in scientific studies, while little is known about some others.

Everybody's microbiome composition is different and science tells us that the functional capacity of the microbiome is more important than which species inhabit it.

| Phylum         | Species                                    | Range            | You   | Level   |
|----------------|--------------------------------------------|------------------|-------|---------|
| Firmicutes_A   | <i>CAG-103 sp</i>                          | 0 ~ 0.8 %        | 0.5 % | AVERAGE |
| Firmicutes_A   | <i>CAG-170 sp</i>                          | 0 ~ 0.3 %        | 0.3 % | HIGH    |
| Firmicutes_A   | <i>CAG-45 sp</i>                           | 0 ~ 0.0 %        | 2.2 % | HIGH    |
| Firmicutes_A   | <i>CAG-81 sp</i>                           | 0 ~ 0.1 %        | 0.1 % | AVERAGE |
| Firmicutes_A   | <i>CAG-83 sp2</i>                          | 0 ~ 0.9 %        | 2.4 % | HIGH    |
| Firmicutes_A   | <i>D16 phoceensis</i>                      | 0 ~ 0.1 %        | 0.2 % | HIGH    |
| Firmicutes_A   | <i>ER4 sp</i>                              | 0 ~ 0.7 %        | 1.0 % | HIGH    |
| Firmicutes_A   | <i>ER4 sp1</i>                             | 0 ~ 1.1 %        | 1.8 % | HIGH    |
| Firmicutes_A   | <i>Faecalibacterium prausnitzii_A</i>      | 0 ~ 2.8 %        | 3.5 % | HIGH    |
| Firmicutes_A   | <i>Faecalibacterium prausnitzii_C</i>      | 0 ~ 2.6 %        | 1.8 % | AVERAGE |
| Firmicutes_A   | <i>Faecalibacterium sp</i>                 | 0.093073 ~ 1.3 % | 0.3 % | AVERAGE |
| Firmicutes_A   | <i>Negativibacillus sp</i>                 | 0 ~ 0.0 %        | 0.5 % | HIGH    |
| Firmicutes_A   | <i>Oscillibacter sp</i>                    | 0 ~ 0.2 %        | 0.3 % | HIGH    |
| Firmicutes_A   | <i>Oscillibacter sp</i>                    | 0 ~ 0.2 %        | 1.0 % | HIGH    |
| Firmicutes_A   | <i>Oscillibacter sp</i>                    | 0 ~ 0.3 %        | 0.8 % | HIGH    |
| Firmicutes_A   | <i>Ruminiclostridium_E siraeum</i>         | 0 ~ 1.8 %        | 0.9 % | AVERAGE |
| Firmicutes_A   | <i>UBA1394 sp</i>                          | 0 ~ 0.2 %        | 0.1 % | AVERAGE |
| Firmicutes_A   | <i>UBA7597 sp</i>                          | 0 ~ 0.0 %        | 0.2 % | HIGH    |
| Firmicutes_C   | <i>Phascolarctobacterium succinatutens</i> | 0 ~ 0.0 %        | 2.1 % | HIGH    |
| Mucoromycota   | <i>Lichtheimia hongkongensis</i>           | 0 ~ 0.0 %        | 0.0 % | AVERAGE |
| Nematoda       | <i>Enterobius vermicularis</i>             | 0 ~ 0.0 %        | 0.0 % | AVERAGE |
| Proteobacteria | <i>Sutterella sp3</i>                      | 0 ~ 0.9 %        | 1.4 % | HIGH    |



# Supplement

- 
- References

# References

- ABRATT, V. R. & REID, S. J. 2010. Oxalate-degrading bacteria of the human gut as probiotics in the management of kidney stone disease. *Adv Appl Microbiol*, 72, 63-87.
- ACHTMAN, M., ZURTH, K., MORELLI, G., TORREA, G., GUIYOULE, A. & CARNIEL, E. 1999. *Yersinia pestis*, the cause of plague, is a recently emerged clone of *Yersinia pseudotuberculosis*. *PNAS USA*, 96, 14043-14048.
- AFSHARI, A., BARATPOUR, A., KHANZADE, S. & JAMSHIDI, A. 2018. *Salmonella enteritidis* and *Salmonella typhimurium* identification in poultry carcasses. *Iran J Microbiol*, 10, 45-50.
- ALLEN-VERCOE, E. 2015. *Fusobacterium varium* in ulcerative colitis: is it population-based? *Dig Dis Sci*, 60, 7-8.
- ALLISON, M. J., COOK, H. M., MILNE, D. B., GALLAGHER, S. & CLAYMAN, R. V. 1986. Oxalate degradation by gastrointestinal bacteria from humans. *J Nutr*, 116, 455-460.
- AMOR, A., ENRIQUEZ, A., CORCUERA, M. T., TORO, C., HERRERO, D. & BAQUERO, M. 2011. Is infection by dermatophilus congolensis underdiagnosed? *J CLIN MICROBIOL*, 49, 449-451.
- ANDINO, A. & HANNING, I. 2015. *Salmonella enterica*: survival, colonization, and virulence differences among serovars. *ScientificWorldJournal*, 2015, 520179.
- ARREDONDO-ALONSO, S., TOP, J., SCHPARCH, A. C., MCNALLY, A., PURANEN, S., PESONEN, M., PENSAR, J., MARTTINEN, P., BRAAT, J. C., ROGERS, M. R., VAN SCHAIK, W., KASKI, S., CORANDER, J. & WILLEMS, R. J. 2019. Genomes of a major nosocomial pathogen *Enterococcus faecium* are shaped by adaptive evolution of the chromosome and plasmidome. *bioRxiv*, 530725.
- ARUMUGAM, M., RAES, J., PELLETIER, E., LE PASLIER, D., YAMADA, T., MENDE, D. R., FERNANDES, G. R., TAP, J., BRULS, T., BATTO, J. M., BERTALAN, M., BORRUEL, N., CASELLAS, F., FERNANDEZ, L., GAUTIER, L., HANSEN, T., HATTORI, M., HAYASHI, T., KLEEREBEZEM, M., KUOKAWA, K., LECLERC, M., LEVENEZ, F., MANICHANH, C., NIELSEN, H. B., NIELSEN, T., PONS, N., POULAIN, J., QIN, J., SICHERITZ-PONTEN, T., TIMS, S., TORRENTS, D., UGARTE, E., ZOETENDAL, E. G., WANG, J., GUARNER, F., PEDERSEN, O., DE VOS, W. M., BRUNAK, S., DORE, J., ANTOLIN, M., ARTIGUENAVE, F., BLOTTIERE, H. M., ALMEIDA, M., BRECHOT, C., CARA, C., CHERVAUX, C., CULTRONE, A., DELORME, C., DENARIAZ, G., DERYN, R., FOERSTNER, K. U., FRISS, C., VAN DE GUCHTE, M., GUEDON, E., HAIMET, F., HUBER, W., VAN HYLCKAMA-VLIEG, J., JAMET, A., JUSTE, C., KACI, G., KNOL, J., LAKHDARI, O., LAYEC, S., LE ROUX, K., MAGUIN, E., MERIEUX, A., MELO MINARDI, R., M'INI, C., MULLER, J., OOOZEER, R., PARKHILL, J., RENAULT, P., RESCIGNO, M., SANCHEZ, N., SUNAGAWA, S., TORREJON, A., TURNER, K., VANDEMEULEBROUCK, G., VARELA, E., WINOGRADSKY, Y., ZELLER, G., WEISSENBACH, J., EHRlich, S. D. & BORK, P. 2011. Enterotypes of the human gut microbiome. *Nature*, 473, 174-80.
- AYDIN, S. 2017. Can vitamin K synthesis altered by dysbiosis of microbiota be blamed in the etiopathogenesis of venous thrombosis? *Biosci Microbiota Food Health*, 36, 73-74.
- BAE, J. Y., KIM, J. I., PARK, S., YOO, K., KIM, I. H., JOO, W., RYU, B. H., PARK, M. S., LEE, I. & PARK, M. S. 2018. Effects of *Lactobacillus plantarum* and *Leuconostoc mesenteroides* probiotics on human seasonal and avian influenza viruses. *J Microbiol Biotechnol*, 28, 893-901.
- BARBOSA, J., BORGES, S. & TEIXEIRA, P. 2015. *Pediococcus acidilactici* as a potential probiotic to be used in food industry. *Int J Food Sci*, 50, 1151-1157.
- BERNAL, I., HOFMANN, J. D., BULLITA, B., KLAUWONN, F., MICHEL, A.-M., JAHN, D., NEUMANN-SCHAAL, M., BRUDER, D. & JæNSCH, L. 2018. *Clostridioides difficile* activates human mucosal-associated invariant T cells. *Front Microbiol*, 9.
- BIBBO, S., IANIRO, G., GIORGIO, V., SCALDAFERRI, F., MASUCCI, L., GASBARRINI, A. & CAMMAROTA, G. 2016. The role of diet on gut microbiota composition. *Eur Rev Med Pharmacol Sci*, 20, 4742-4749.
- BIER, A., BRAUN, T., KHASBAB, R., DI SEGNI, A., GROSSMAN, E., HABERMAN, Y. & LEIBOWITZ, A. 2018. A high salt diet modulates the gut microbiota and short chain fatty acids production in a salt-sensitive hypertension rat model. *Nutrients*, 10.
- BLASER, M. J. 1998. *Helicobacter pylori* and gastric diseases. *BMJ (Clinical research ed.)*, 316, 1507-1510.
- BLUNDON, M. A., PARK, A., KEITH, S. A., OLIVER, S. L., EUTSEY, R. A., PYZEL, A. M., LAU, T. W., HUANG, J. H., KOLEV, H. M., LUISA HILLER, N., ATKINSON, N. S., MINDEN, J. S. & MCCARTNEY, B. M. 2018. Microbiota-dependent elevation of alcohol dehydrogenase in *Drosophila* is associated with changes in alcohol-induced hyperactivity and alcohol preference. *bioRxiv*, 444471.
- BOMKO, T. V., NOSALSKAYA, T. N., KABLUCHKO, T. V., LISNYAK, Y. V. & MARTYNOV, A. V. 2016. Immunotropic aspect of the *Bacillus coagulans* probiotic action. *bioRxiv*, 088757.
- BORREL, G., MCCANN, A., DEANE, J., NETO, M. C., LYNCH, D. B., BRUGERE, J. F. & O'TOOLE, P. W. 2017. Genomics and metagenomics of trimethylamine-utilizing Archaea in the human gut microbiome. *ISME j*, 11, 2059-2074.
- BOSTANCI, N. & BELIBASAKIS, G. N. 2012. *Porphyromonas gingivalis*: an invasive and evasive opportunistic oral pathogen. *FEMS Microbiology Letters*, 333, 1-9.
- BOTTONE, E. J. 2010. *Bacillus cereus*, a volatile human pathogen. *Clin Microbiol Rev*, 23, 382-398.
- BRANDAL, L. T., TUNSIJ, H. S., RANHEIM, T. E., LÜBERSLI, I., LANGE, H. & WESTER, A. L. 2015. Shiga toxin 2a in *Escherichia albertii*. *J Clin Microbiol*, 53, 1454-1455.
- BRAUN, H.-S., SPONDER, G., PIEPER, R., ASCHENBACH, J. R. & DEINER, C. 2015. GABA selectively increases mucin-1 expression in isolated pig jejunum. *Genes Nutr*, 10, 47.
- BRENNER, D. M. & CHEY, W. D. 2009. *Bifidobacterium infantis* 35624: a novel probiotic for the treatment of irritable bowel syndrome. *Rev Gastroenterol Disord*, 9, 7-15.
- BROSS, M. H., SOCH, K., MORALES, R. & MITCHELL, R. B. 2007. *Vibrio vulnificus* infection: diagnosis and treatment. *Am Fam Physician*, 76, 539-44.
- BURD, E. M., JUZYCH, L. A., RUDRIK, J. T. & HABIB, F. 2007. Pustular dermatitis caused by dermatophilus congolensis. *J Clin Microbiol*, 45, 1655-1658.
- CAPOOR, M. N., BIRKENMAIER, C., WANG, J. C., MCDOWELL, A., AHMED, F. S., BRUGGEMANN, H., COSCIA, E., DAVIES, D. G., OHRT-NISSEN, S., RAZ, A., RUZICKA, F., SCHMITZ, J. E., FISCHETTI, V. A. & SLABY, O. 2019. A review of microscopy-based evidence for the association of *Propionibacterium acnes* biofilms in degenerative disc disease and other diseased human tissue. *Eur Spine J*.
- CHNG, S. L., OCTAVIA, S., XIA, Q., DUONG, A., TANAKA, M. M., FUKUSHIMA, H. & LAN, R. 2011. Population structure and evolution of pathogenicity of *Yersinia pseudotuberculosis*. *Appl Environ Microbiol*, 77, 768-775.
- CHAUDHURI, D., ROY CHOWDHURY, A., BISWAS, B. & CHAKRAVORTY, D. 2018. *Salmonella typhimurium* infection leads to colonization of the mouse brain and is not completely cured with antibiotics. *Front Microbiol*, 9.
- CHHIBBER-GOEL, J., GAUR, A., SINGHAL, V., PARAKH, N., BHARGAVA, B. & SHARMA, A. 2016. The complex metabolism of trimethylamine in humans: endogenous and exogenous sources. *Expert Rev Mol Med*, 18, e8.
- CILLONIZ, C., MARTIN-LOECHES, I., GARCIA-VIDAL, C., SAN JOSE, A. & TORRES, A. 2016. Microbial etiology of *Pneumonia*: epidemiology, diagnosis and resistance patterns. *Int J Mol Sci*, 17, 2120.
- CLARKE, S. F., MURPHY, E. F., NILAWEERA, K., ROSS, P. R., SHANAHAN, F., O'TOOLE, P. W. & COTTER, P. D. 2012. The gut microbiota and its relationship to diet and obesity: new insights. *Gut microbes*, 3, 186-202.
- COOKE, G., BEHAN, J. & COSTELLO, M. 2006. Newly identified vitamin K-producing bacteria isolated from the neonatal faecal flora. *Microb Ecol Health Dis*, 18, 133-138.
- COVER, T. L. & BLASER, M. J. 2009. *Helicobacter pylori* in health and disease. *Gastroenterology*, 136, 1863-1873.
- CUTTING, S. M. 2011. *Bacillus* probiotics. *Food Microbiol*, 28, 214-20.
- DAMODHARAN, K., LEE, Y. S., PALANIYANDI, S. A., YANG, S. H. & SUH, J.-W. 2015. Preliminary probiotic and technological characterization of *Pediococcus pentosaceus* strain KID7 and *in vivo* assessment of its cholesterol-lowering activity. *Front Microbiol*, 6, 768-768.
- DAVID, R. 2013. The road to *E. faecium* pathogenesis. *Nat Rev Microbiol*, 11, 662.
- DELOGU, G., SALI, M. & FADDA, G. 2013. The biology of *Mycobacterium tuberculosis* infection. *Mediterr J Hematol Infect Dis* 5, e2013070-e2013070.
- DERRIEN, M., BELZER, C. & DE VOS, W. M. 2012. *Akkermansia muciniphila* and its role in regulating host functions. *Microb Pathog*, 106, 171-181.
- DHAKAL, R., BAJPAI, V. K. & BAEK, K. H. 2012. Production of GABA (gamma - aminobutyric acid) by microorganisms: a review. *Braz J Microbiol*, 43, 1230-1241.
- DODD, D., SPITZER, M. H., VAN TREUREN, W., MERRILL, B. D., HRYCKOWIAN, A. J., HIGGINBOTTOM, S. K., LE, A., COWAN, T. M., NOLAN, G. P., FISCHBACH, M. A. & SONNENBURG, J. L. 2017. A gut bacterial pathway metabolizes aromatic amino acids into nine circulating metabolites. *Nature*, 551, 648-652.
- DREVETS, D. A. & BRONZE, M. S. 2008. *Listeria monocytogenes* : epidemiology, human disease, and mechanisms of brain invasion. *Pathog Dis*, 53, 151-165.
- DU PREZ, S., CORBITT, M., CABANAS, H., EATON, N., STAINES, D. & MARSHALL-GRADISNIK, S. 2018. A systematic review of enteric dysbiosis in chronic fatigue syndrome/myalgic encephalomyelitis. *Syst Rev*, 7, 241.
- DUBINKINA, V. B., TYAKHT, A. V., ODINTSOVA, V. Y., YARYGIN, K. S., KOVARSKY, B. A., PAVLENKO, A. V., ISCHENKO, D. S., POPENKO, A. S., ALEXEEV, D. G., TARASKINA, A. Y., NASYROVA, R. F., KRUPITSKY, E. M., SHALIKIANI, N. V., BAKULIN, I. G., SHCHERBAKOV, P. L., SKORODUMOVA, L. O., LARIN, A. K., KOSTRYUKOVA, E. S., ABDULKHAKOV, R. A., ABDULKHAKOV, S. R., MALANIN, S. Y., ISMAGILOVA, R. K., GRIGORYEVA, T. V., ILINA, E. N. & GOVORUN, V. M. 2017. Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease. *Microbiome*, 5, 141.
- DURACK, J. & LYNCH, S. V. 2019. The gut microbiome: relationships with disease and opportunities for therapy. *J Exp Med*, 216, 20-40.
- EL HAGE, R., HERNANDEZ-SANABRIA, E., CALATAYUD ARROYO, M., PROPS, R. & VAN DE WIELE, T. 2019. Propionate-producing consortium restores antibiotic-induced

- dysbiosis in a dynamic *in vitro* model of the human intestinal microbial ecosystem. *Front Microbiol*, 10, 1206.
- ELSHAGHABEE, F. M. F., ROKANA, N., GULHANE, R. D., SHARMA, C. & PANWAR, H. 2017. *Bacillus* as potential probiotics: status, concerns, and future perspectives. *Front Microbiol*, 8, 1490-1490.
- ENGEL, P. A., GREEN, S. J., VOIGT, R. M., FORSYTH, C. B. & KESHAVARZIAN, A. 2015. The gastrointestinal microbiome: alcohol effects on the composition of intestinal microbiota. *Alcohol Res*, 37, 223-236.
- ESCOBAR-ZEPEDA, A., GODOY-LOZANO, E. E., RAGGI, L., SEGOVIA, L., MERINO, E., GUTIÉRREZ-RIOS, R. M., JUAREZ, K., LICEA-NAVARRO, A. F., PARDO-LOPEZ, L. & SANCHEZ-FLORES, A. 2018. Analysis of sequencing strategies and tools for taxonomic annotation: defining standards for progressive metagenomics. *Scientific Reports*, 8, 12034.
- FARBER, J. M. & PETERKIN, P. I. 1991. *Listeria monocytogenes*, a food-borne pathogen. *Microbiological reviews*, 55, 476-511.
- FARUQUE, S. M., ALBERT, M. J. & MEKALANOS, J. J. 1998. Epidemiology, genetics, and ecology of toxigenic *Vibrio cholerae*. *Microbiol Mol Biol Rev*, 62, 1301-14.
- FENNEMA, D., PHILLIPS, I. R. & SHEPARD, E. A. 2016. Trimethylamine and trimethylamine N-oxide, a flavin-containing monooxygenase 3 (FMO3)-mediated host-microbiome metabolic axis implicated in health and disease. *Drug Metab Dispos*, 44, 1839-1850.
- FERGUSON, R. M. W., MERRIFIELD, D. L., HARPER, G. M., RAWLING, M. D., MUSTAFA, S., PICCHIETTI, S., BALCÁZAR, J. L. & DAVIES, S. J. 2010. The effect of *Pediococcus acidilactici* on the gut microbiota and immune status of on-growing red tilapia (*Oreochromis niloticus*). *J Appl Microbiol*, 109, 851-862.
- FLINT, H. J., SCOTT, K. P., DUNCAN, S. H., LOUIS, P. & FORANO, E. 2012. Microbial degradation of complex carbohydrates in the gut. *Gut Microbes*, 3, 289-306.
- FORSTEN, S. D., BJØRKLUND, M. & OUWEHAND, A. C. 2010. *Streptococcus mutans*, caries and simulation models. *Nutrients*, 2, 290-298.
- GAO, J., XU, K., LIU, H., LIU, G., BAI, M., PENG, C., LI, T. & YIN, Y. 2018. Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. *Front Cell Infect Microbiol*, 8, 13.
- GILOTEAUX, L., GOODRICH, J. K., WALTERS, W. A., LEVINE, S. M., LEY, R. E. & HANSON, M. R. 2016. Reduced diversity and altered composition of the gut microbiome in individuals with myalgic encephalomyelitis/chronic fatigue syndrome. *Microbiome*, 4, 30.
- GIORNO, R., BOZUE, J., COTE, C., WENZEL, T., MOODY, K.-S., MALLOZZI, M., RYAN, M., WANG, R., ZIELKE, R., MADDOCK, J. R., FRIEDLANDER, A., WELKOS, S. & DRIKS, A. 2007. Morphogenesis of the *Bacillus anthracis* spore. *J Bacteriol*, 189, 691-705.
- GRANUM, P. E. & LUND, T. 1997. *Bacillus cereus* and its food poisoning toxins. *FEMS Microbiology Letters*, 157, 223-228.
- GRONBACH, K., EBERLE, U., MÜLLER, M., OLSCHLÄGER, T. A., DOBRINDT, U., LEITHÄUSER, F., NIESS, J. H., DØRING, G., REIMANN, J., AUTENRIETH, I. B. & FRICK, J.-S. 2010. Safety of probiotic *Escherichia coli* strain Nissle 1917 depends on intestinal microbiota and adaptive immunity of the host. *Infect Immun*, 78, 3036-3046.
- GUH, A. Y. & KUTTY, P. K. 2018. *Clostridioides difficile* infection. *Annals of Internal Medicine*, 169, ITC49-ITC64.
- GUPTA, V. K., PAUL, S. & DUTTA, C. 2017. Geography, ethnicity or subsistence-specific variations in human microbiome composition and diversity. *Front Microbiol*, 8, 1162.
- GURUNG, N., RAY, S., BOSE, S. & RAI, V. 2013. A broader view: microbial enzymes and their relevance in industries, medicine, and beyond. *Biomed Res Int*, 2013, 329121-329121.
- HAN, Y. W. 2015. *Fusobacterium nucleatum*: a commensal-turned pathogen. *Curr Opin Microbiol*, 23, 141-147.
- HANAI, T., ATSUMI, S. & LIAO, J. C. 2007. Engineered synthetic pathway for isopropanol production in *Escherichia coli*. *Appl Environ Microbiol*, 73, 7814-7818.
- HARADA, K., AMANO, K., AKIMOTO, S., YAMAMOTO, K., YAMAMOTO, Y., YANAGIHARA, K., KOHNO, S., KISHIDA, N. & TAKAHASHI, T. 2011. Serological and pathogenic characterization of *Enterococcus faecalis* isolates from two human cases of endocarditis in Japan. *New Microbiol*, 34, 409-12.
- HEIDARI, H., HASANPOUR, S., EBRAHIM-SARAEI, H. S. & MOTAMEDIFAR, M. 2017. High incidence of virulence factors among clinical *Enterococcus faecalis* isolates in Southwestern Iran. *Infect Chemother*, 49, 51-56.
- HENRIQUES-NORMARK, B. & TUOMANEN, E. I. 2013. The pneumococcus: epidemiology, microbiology, and pathogenesis. *Cold Spring Harb Perspect Med*, 3, a010215.
- HIRAI, Y., ASAHATA-TAGO, S., AINODA, Y., FUJITA, T. & KIKUCHI, K. 2015. *Edwardsiella tarda* bacteremia. A rare but fatal water- and foodborne infection: review of the literature and clinical cases from a single centre. *Can J Infect Dis Med Microbiol*, 26, 313-318.
- HOW, K. Y., SONG, K. P. & CHAN, K. G. 2016. *Porphyromonas gingivalis*: an overview of periodontopathic pathogen below the gum line. *Front Microbiol*, 7, 53-53.
- HOYLES, L., JIMENEZ-PRANTEDA, M. L., CHILLOUX, J., BRIAL, F., MYRIDAKIS, A., ARANIAS, T., MAGNAN, C., GIBSON, G. R., SANDERSON, J. D., NICHOLSON, J. K., GAUGUIER, D., MCCARTNEY, A. L. & DUMAS, M. E. 2018. Metabolic retroconversion of trimethylamine N-oxide and the gut microbiota. *Microbiome*, 6, 73.
- HUGHES, R., MAGEE, E. A. & BINGHAM, S. 2000. Protein degradation in the large intestine: relevance to colorectal cancer. *Curr Issues Intest Microbiol*, 1, 51-58.
- JANEIRO, M. H., RAMIREZ, M. J., MILAGRO, F. I., MARTINEZ, J. A. & SOLAS, M. 2018. Implication of trimethylamine n-oxide (TMAO) in disease: potential biomarker or new therapeutic target. *Nutrients*, 10.
- JENNISON, A. V. & VERMA, N. K. 2004. *Shigella flexneri* infection: pathogenesis and vaccine development. *FEMS Microbiology Reviews*, 28, 43-58.
- JONES, M. K. & OLIVER, J. D. 2009. *Vibrio vulnificus*: disease and pathogenesis. *Infect Immun*, 77, 1723-1733.
- JOSE, P. A. & RAJ, D. 2015. Gut microbiota in hypertension. *Curr Opin Nephrol Hypertens*, 24, 403-409.
- KAU, A. L., MARTIN, S. M., LYON, W., HAYES, E., CAPARON, M. G. & HULTGREN, S. J. 2005. *Enterococcus faecalis* tropism for the kidneys in the urinary tract of C57BL/6J mice. *Infect Immun*, 73, 2461-2468.
- KHAN, S. R. 1995. *Calcium oxalate in biological systems*.
- KIM, J. E. & KIM, H. S. 2019. Microbiome of the skin and gut in atopic dermatitis (AD): understanding the pathophysiology and finding novel management strategies. *J Clin Med*, 8, 444.
- KING, P. 2012. *Haemophilus influenzae* and the lung (Haemophilus and the lung). *Clin Transl Med*, 1, 10-10.
- KINROSS, J. M., DARZI, A. W. & NICHOLSON, J. K. 2011. Gut microbiome-host interactions in health and disease. *Genome Medicine*, 3, 14.
- KO, J. S. 2013. The intestinal microbiota and human disease. *Korean J Gastroenterol*, 62, 85-91.
- KONURAY, G. & ERGINKAYA, Z. 2018. Potential use of *Bacillus coagulans* in the food industry. *Foods (Basel, Switzerland)*, 7, 92.
- KOROPATKIN, N. M., CAMERON, E. A. & MARTENS, E. C. 2012. How glycan metabolism shapes the human gut microbiota. *Nat Rev Microbiol*, 10, 323-335.
- KOVACHEVA-DATCHARY, P. & ARORA, T. 2013. Nutrition, the gut microbiome and the metabolic syndrome. *Best Pract Res Clin Gastroenterol*, 27, 59-72.
- KUHM, A. E., SUTER, D., FELLEISEN, R. & RAU, J. 2009. Identification of *Yersinia enterocolitica* at the species and subspecies levels by fourier transform infrared spectroscopy. *Appl Environ Microbiol*, 75, 5809-5813.
- LEE, S. Y., LEE, E., PARK, Y. M. & HONG, S. J. 2018. Microbiome in the gut-skin axis in atopic dermatitis. *Allergy Asthma Immunol Res*, 10, 354-362.
- LI, Y.-Y., GE, Q.-X., CAO, J., ZHOU, Y.-J., DU, Y.-L., SHEN, B., WAN, Y.-J. Y. & NIE, Y.-Q. 2016. Association of *Fusobacterium nucleatum* infection with colorectal cancer in Chinese patients. *World J Gastroenterol*, 22, 3227-3233.
- LIN, H. V., FRASSETTO, A., KOWALIK, E. J., JR., NAWROCKI, A. R., LU, M. M., KOSINSKI, J. R., HUBERT, J. A., SZETO, D., YAO, X., FORREST, G. & MARSH, D. J. 2012. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. *PLoS One*, 7, e35240.
- LOUIS, P. & FLINT, H. J. 2017. Formation of propionate and butyrate by the human colonic microbiota. *Environ Microbiol*, 19, 29-41.
- MARCOBAL, A., DE LAS RIVAS, B., LANDETE, J. M., TABERA, L. & MUNOZ, R. 2012. Tyramine and phenylethylamine biosynthesis by food bacteria. *Crit Rev Food Sci Nutr*, 52, 448-467.
- MARIAT, D., FIRMESSE, O., LEVENEZ, F., GUIMARÃES, V., SOKOL, H., DORÉ, J., CORTIER, G. & FURET, J. P. 2009. The *Firmicutes/Bacteroidetes* ratio of the human microbiota changes with age. *BMC Microbiol*, 9, 123.
- MARTENS, E. C., LOWE, E. C., CHIANG, H., PUDLO, N. A., WU, M., MCNULTY, N. P., ABBOTT, D. W., HENRISSAT, B., GILBERT, H. J., BOLAM, D. N. & GORDON, J. I. 2011. Recognition and degradation of plant cell wall polysaccharides by two human gut symbionts. *PLoS Biol*, 9, e1001221.
- MASSON, F., TALON, R. & MONTEL, M. C. 1996. Histamine and tyramine production by bacteria from meat products. *Int J Food Microbiol*, 32, 199-207.
- MCLENDON, M. K., APICELLA, M. A. & ALLEN, L.-A. H. 2006. *Francisella tularensis*: taxonomy, genetics, and immunopathogenesis of a potential agent of biowarfare. *Annu Rev Microbiol*, 60, 167-185.
- MILLION, M., TIDJANI ALOU, M., KHELAIFA, S., BACHAR, D., LAGIER, J.-C., DIONE, N., BRAH, S., HUGON, P., LOMBARD, V., ARMOUGOM, F., FROMONOT, J., ROBERT, C., MICHELLE, C., DIALLO, A., FABRE, A., GUIEU, R., SOKHNA, C., HENRISSAT, B., PAROLA, P. & RAOULT, D. 2016. Increased gut redox and depletion of anaerobic and methanogenic prokaryotes in severe acute malnutrition. *Sci Rep*, 6, 26051.
- MINAMI, M., ANDO, T., OKAMOTO, A., SASAKI, N., OHKURA, T., TORII, K., HASEGAWA, T., OHTA, M. & GOTO, H. 2009. Seroprevalence of *Fusobacterium varium* in ulcerative colitis patients in Japan. *Pathog Dis*, 56, 67-72.
- MISSAILIDIS, D., ANNESLEY, S. J. & FISHER, P. R. 2019. Pathological mechanisms underlying myalgic encephalomyelitis/chronic fatigue syndrome. *Diagnostics (Basel)*, 9.
- MUKUNDAN, D., ECEVIT, Z., PATEL, M., MARRS, C. F. & GILSDORF, J. R. 2007. Pharyngeal colonization dynamics of *Haemophilus influenzae* and *Haemophilus haemolyticus* in healthy adult carriers. *J Clin Microbiol*, 45, 3207-3217.
- MUTAGUCHI, Y., KASUGA, K. & KOJIMA, I. 2018. Production of d-branched-chain amino acids by lactic acid bacteria carrying homologs to isoleucine 2-epimerase of *Lactobacillus buchneri*. *Front Microbiol*, 9, 1540.

- NAKANO, K., NOMURA, R. & OOSHIMA, T. 2008. *Streptococcus mutans* and cardiovascular diseases. *Japanese Dental Science Review*, 44, 29-37.
- NASKALI, E., DETTMER, K., OFNER, P. J., PEREIRA, P. A. B., KROHN, K., AUVINEN, P., RANKI, A. & KLUGER, N. 2019. Serotonin and tryptophan metabolites, autoantibodies and gut microbiome in APECED. *Endocr Connect*, 8, 69-77.
- NEWBERRY, F., HSIEH, S. Y., WILEMAN, T. & CARDING, S. R. 2018. Does the microbiome and virome contribute to myalgic encephalomyelitis/chronic fatigue syndrome? *Clin Sci (Lond)*, 132, 523-542.
- NOSOVA, T., JOELAINEN, K., KAIHOVAARA, P., JOUSIMIES-SOMER, H., SIITONEN, A., HEINE, R. & SALASPURO, M. 1996. Aldehyde dehydrogenase activity and acetate production by aerobic bacteria representing the normal flora of human large intestine. *Alcohol Alcohol*, 31, 555-564.
- NOSOVA, T., JOUSIMIES-SOMER, H., JOELAINEN, K., HEINE, R. & SALASPURO, M. 2000. Acetaldehyde production and metabolism by human indigenous and probiotic *Lactobacillus* and *Bifidobacterium* strains. *Alcohol Alcohol*, 35, 561-568.
- O'MAHONY, S. M., CLARKE, G., BORRE, Y. E., DINAN, T. G. & CRYAN, J. F. 2015. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. *Behav Brain Res*, 277, 32-48.
- OLIPHANT, K. & ALLEN-VERCOE, E. 2019. Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health. *Microbiome*, 7, 91.
- OTTO, M. 2014. *Staphylococcus aureus* toxins. *Curr Opin Microbiol*, 17, 32-37.
- PARK, H. E., KANG, K. W., KIM, B. S., LEE, S. M. & LEE, W. K. 2017. Immunomodulatory potential of *Weissella cibaria* in aged C57BL/6J mice. *J Microbiol Biotechnol*, 27, 2094-2103.
- PARK, Y. S., KANG, J., CHUNG, W. H., LIM, M. Y., SEO, M. J., NAM, Y. D., YOON, J. H. & SEO, D. H. 2019. Complete genome sequence of acetate-producing *Klebsiella pneumoniae* L5-2 isolated from infant feces. *3 Biotech*, 9, 84.
- PEDERSEN, H. K., GUDMUNDSDOTTIR, V., NIELSEN, H. B., HYOTYLAINEN, T., NIELSEN, T., JENSEN, B. A. H., FORSLUND, K., HILDEBRAND, F., PRIFTI, E., FALONY, G., LE CHATELIER, E., LEVENEZ, F., DORÉ, J., MATTILA, I., PLICHTA, D. R., PØHØ, P., HELLGREN, L. I., ARUMUGAM, M., SUNAGAWA, S., VIEIRA-SILVA, S., JØRGENSEN, T., HOLM, J. B., TROŠT, K., CONSORTIUM, M., KRISTIANSEN, K., BRIS, S., RAES, J., WANG, J., HANSEN, T., BORK, P., BRUNAK, S., ORESIC, M., EHRlich, S. D. & PEDERSEN, O. 2016. Human gut microbes impact host serum metabolome and insulin sensitivity. *Nature*, 535, 376-381.
- PETERSEN, C. 2005. D-lactic acidosis. *Nutr Clin Pract*, 20, 634-645.
- PIANTA, A., ARVIKAR, S., STRLE, K., DROUIN, E. E., WANG, Q., COSTELLO, C. E. & STEERE, A. C. 2017. Evidence of the immune relevance of *Prevotella copri*, a gut microbe, in patients with rheumatoid arthritis. *Arthritis Rheumatol*, 69, 964-975.
- PORTUNE, K. J., BEAUMONT, M., DAVILA, A.-M., TOMÉ, D., BLANCHIER, F. & SANZ, Y. 2016. Gut microbiota role in dietary protein metabolism and health-related outcomes: The two sides of the coin. *Trends Food Sci Technol*, 57, 213-232.
- PROCTOR, L. M., CREASY, H. H., FETTWEIS, J. M., LLOYD-PRICE, J., MAHURKAR, A., ZHOU, W., BUCK, G. A., SNYDER, M. P., STRAUSS, J. F., WEINSTOCK, G. M., WHITE, O., HUTTENHOWER, C. & THE INTEGRATIVE, H. M. P. R. N. C. 2019. The integrative Human Microbiome Project. *Nature*, 569, 641-648.
- R. V. KALAIMATHI, C. K., P. SIVAMANI, D. RAGHUNATHAN 2015. Effectiveness of a *Bacillus megaterium*, as a probiotic in *Salmonella typhimurium* induced infection in rats. *J Pharm Res*, 9, 177-181.
- RAMAKRISHNA, B. S. 2013. Role of the gut microbiota in human nutrition and metabolism. *J Gastroenterol Hepatol*, 28, 9-17.
- REBOLI, A. C. & FARRAR, W. E. 1989. *Erysipelothrix rhusiopathiae*: an occupational pathogen. *Clinical Microbiology Reviews*, 2, 354-359.
- REIDL, J. & KLOSE, K. E. 2002. *Vibrio cholerae* and cholera: out of the water and into the host. *FEMS Microbiology Reviews*, 26, 125-139.
- RIORDAN, T. 2007. Human infection with *Fusobacterium necrophorum* (Necrobacillosis), with a focus on Lemierre's syndrome. *Clin Microbiol Rev*, 20, 622-659.
- RIVERA, F. P., MEDINA, A. M., ALDASORO, E., SANGIL, A., GASCON, J., OCHOA, T. J., VILA, J. & RUIZ, J. 2013. Genotypic characterization of enterotoxigenic *Escherichia coli* strains causing traveler's diarrhea. *J Clin Microbiol*, 51, 633-635.
- RIVIÈRE, A., SELAK, M., LANTIN, D., LEROY, F. & DE VUYST, L. 2016. *Bifidobacteria* and butyrate-producing colon bacteria: Importance and strategies for their stimulation in the human gut. *Front Microbiol*, 7, 979.
- ROAGER, H. M. & LICHT, T. R. 2018. Microbial tryptophan catabolites in health and disease. *Nat Commun*, 9, 3294.
- ROWE, H. M. & HUNTLEY, J. F. 2015. From the outside-in: the *Francisella tularensis* envelope and virulence. *Front Cell Infect Microbiol*, 5.
- RUSSELL, W. R., HOYLES, L., FLINT, H. J. & DUMAS, M. E. 2013. Colonic bacterial metabolites and human health. *Curr Opin Microbiol*, 16, 246-254.
- SABINA, Y., RAHMAN, A., RAY, R. C. & MONTET, D. 2011. *Yersinia enterocolitica*: mode of transmission, molecular insights of virulence, and pathogenesis of infection. *J Pathog*, 2011, 429069.
- SAEY, D., MICHAUD, A., COUILLARD, A., COTE, C. H., MADOR, M. J., LEBLANC, P., JOBIN, J. & MALTAIS, F. 2005. Contractile fatigue, muscle morphometry, and blood lactate in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 171, 1109-1115.
- SALASPURO, V., NYFORS, S., HEINE, R., SIITONEN, A., SALASPURO, M. & JOUSIMIES-SOMER, H. 1999. Ethanol oxidation and acetaldehyde production *in vitro* by human intestinal strains of *Escherichia coli* under aerobic, microaerobic, and anaerobic conditions. *Scand J Gastroenterol*, 34, 967-973.
- SALEM, I., RAMSER, A., ISHAM, N. & GHANNOUM, M. A. 2018. The gut microbiome as a major regulator of the gut-skin axis. *Front Microbiol*, 9, 1459-1459.
- SAMPSON, TIMOTHY R. & MAZMANIAN, SARKIS K. 2015. Control of brain development, function, and behavior by the microbiome. *Cell Host Microbe*, 17, 565-576.
- SARKAR, A., LEHTO, S. M., HARTY, S., DINAN, T. G., CRYAN, J. F. & BURNET, P. W. J. 2016. Psychobiotics and the manipulation of bacteria-gut-brain signals. *Trends Neurosci*, 39, 763-781.
- SCALDAFERRI, F., GERARDI, V., MANGIOLA, F., LOPETUSO, L. R., PIZZOFERRATO, M., PETITO, V., PAPA, A., STOJANOVIC, J., POSCIA, A., CAMMAROTA, G. & GASBARRINI, A. 2016. Role and mechanisms of action of *Escherichia coli* Nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update. *World J Gastroenterol*, 22, 5505-5511.
- SCHER, J. U., SCZESNAK, A., LONGMAN, R. S., SEGATA, N., UBEDA, C., BIELSKI, C., ROSTRON, T., CERUNDOLO, V., PAMER, E. G., ABRAMSON, S. B., HUTTENHOWER, C. & LITTMAN, D. R. 2013. Expansion of intestinal *Prevotella copri* correlates with enhanced susceptibility to arthritis. *eLife*, 2, e01202-e01202.
- SCOTT, K. P., GRATZ, S. W., SHERIDAN, P. O., FLINT, H. J. & DUNCAN, S. H. 2013. The influence of diet on the gut microbiota. *Pharmacol Res*, 69, 52-60.
- SHAHCHERAGHI, S., AYATOLLAHI, J. & LOTFI, M. 2015. Applications of *Bacillus subtilis* as an important bacterium in medical sciences and human life. *Tropical Journal of Medical Research*, 18, 1-4.
- SHANG, F.-M. & LIU, H.-L. 2018. *Fusobacterium nucleatum* and colorectal cancer: a review. *World J Gastrointest Oncol*, 10, 71-81.
- SHEEDY, J. R., WETTENHALL, R. E., SCANLON, D., GOOLEY, P. R., LEWIS, D. P., MCGREGOR, N., STAPLETON, D. I., BUTT, H. L. & KL, D. E. M. 2009. Increased d-lactic acid intestinal bacteria in patients with chronic fatigue syndrome. *In Vivo*, 23, 621-628.
- SHUKLA, R. & GOYAL, A. 2014. Probiotic potential of *Pediococcus pentosaceus* CRAG3: a new isolate from fermented cucumber. *Probiotics Antimicrob Proteins*, 6, 11-21.
- SINGH, R. K., CHANG, H. W., YAN, D., LEE, K. M., UCMAR, D., WONG, K., ABROUK, M., FARAHNIK, B., NAKAMURA, M., ZHU, T. H., BHUTANI, T. & LIAO, W. 2017. Influence of diet on the gut microbiome and implications for human health. *J Transl Med*, 15, 73.
- SINGH, S., BHATIA, R., SINGH, A., SINGH, P., KAUR, R., KHARE, P., PURAMA, R. K., BOPARAI, R. K., RISHI, P., AMBALAM, P., BHADADA, S. K., BISHNOI, M., KAUR, J. & KONDEPUDI, K. K. 2018. Probiotic attributes and prevention of LPS-induced pro-inflammatory stress in RAW264.7 macrophages and human intestinal epithelial cell line (Caco-2) by newly isolated *Weissella cibaria* strains. *Food Funct*, 9, 1254-1264.
- SLAVEN, E. M., LOPEZ, F. A., HART, S. M. & SANDERS, C. V. 2001. Myonecrosis caused by *Edwardsiella tarda*: a case report and case series of extraintestinal *E. tarda* infections. *Clin Infect Dis*, 32, 1430-1433.
- SMITH, I. 2003. *Mycobacterium tuberculosis* pathogenesis and molecular determinants of virulence. *Clin Microbiol Rev*, 16, 463-496.
- STRANDWITZ, P., KIM, K. H., TEREKHOVA, D., LIU, J. K., SHARMA, A., LEVERING, J., MCDONALD, D., DIETRICH, D., RAMADHAR, T. R., LEKBUA, A., MROUE, N., LISTON, C., STEWART, E. J., DUBIN, M. J., ZENGLER, K., KNIGHT, R., GILBERT, J. A., CLARDY, J. & LEWIS, K. 2019. GABA-modulating bacteria of the human gut microbiota. *Nat Microbiol*, 4, 396-403.
- TAKATA, K., KINOSHITA, M., OKUNO, T., MORIYA, M., KOHDA, T., HONORAT, J. A., SUGIMOTO, T., KUMANOGOH, A., KAYAMA, H., TAKEDA, K., SAKODA, S. & NAKATSUJI, Y. 2011. The lactic acid bacterium *Pediococcus acidilactici* suppresses autoimmune encephalomyelitis by inducing IL-10-producing regulatory T cells. *PLoS One*, 6, e27644-e27644.
- TANG, W. H. & HAZEN, S. L. 2014. The contributory role of gut microbiota in cardiovascular disease. *J Clin Invest*, 124, 4204-4211.
- TEAM, N. H. M. P. A. 2019. A review of 10 years of human microbiome research activities at the US National Institutes of Health, Fiscal Years 2007-2016. *Microbiome*, 7, 31.
- TONG, S. Y. C., DAVIS, J. S., EICHENBERGER, E., HOLLAND, T. L. & FOWLER, V. G. 2015. *Staphylococcus aureus* infections: epidemiology, pathophysiology, clinical manifestations, and management. *Clin Microbiol Rev*, 28, 603-661.
- TORRES-AGUILAR, L., RODRIGUEZ-FRAGOSO, L., GARCIA-VAZQUEZ, F. & REYES-ESPARZA, J. 2017. Effect of probiotic *Pediococcus pentosaceus* on intestinal permeability and occludin protein distribution in a murine model of colitis. *The FASEB Journal*, 31, 657.13-657.13.
- TRAORE, S. I., KHELAIFA, S., ARMSTRONG, N., LAGIER, J. C. & RAOULT, D. 2019. Isolation and culture of *Methanobrevibacter smithii* by co-culture with hydrogen-producing bacteria on agar plates. *Clin Microbiol Infect* 30160.
- TRIVEDI, K. I. B. & KARPISKOVA, R. 2009. Tyramine production by *Enterococci* from various foodstuffs: A threat to the consumers. *Czech J Food Sci*, 27, S357-S360.
- TURNBAUGH, P. J., LEY, R. E., HAMADY, M., FRASER-LIGGETT, C. M., KNIGHT, R. & GORDON, J. I. 2007. The Human Microbiome Project. *Nature*, 449, 804-810.
- TURRONI, S., VITALI, B., BENDAZZOLI, C., CANDELA, M., GOTTI, R., FEDERICI, F., PIROVANO, F. & BRIGIDI, P. 2007. Oxalate consumption by *Lactobacilli*: evaluation of oxalyl-CoA



decarboxylase and formyl-CoA transferase activity in *Lactobacillus acidophilus*. *J Appl Microbiol*, 103, 1600-1609.

VALDES, A. M., WALTER, J., SEGAL, E. & SPECTOR, T. D. 2018. Role of the gut microbiota in nutrition and health. *BMJ*, 361, k2179.

VANDEPUTTE, D., FALONY, G., VIEIRA-SILVA, S., TITO, R. Y., JOOSSENS, M. & RAES, J. 2016. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. *Gut*, 65, 57-62.

VARGA GABRIELLA A., K. E. S. 1997. Microbial and animal limitations to fiber digestion and utilization. *J Nutr*, 127, 819S-823S.

VERDAM, F. J., FUENTES, S., DE JONGE, C., ZOETENDAL, E. G., ERBIL, R., GREVE, J. W., BUURMAN, W. A., DE VOS, W. M. & RENSEN, S. S. 2013. Human intestinal microbiota composition is associated with local and systemic inflammation in obesity. *Obesity (Silver Spring)*, 21, E607-E615.

VITAL, M., KARCH, A. & PIEPER, D. H. 2017. Colonic butyrate-producing communities in humans: an overview using omics data. *mSystems*, 2, e00130-17.

WANG, Y., LI, A., JIANG, X., ZHANG, H., MEHMOOD, K., ZHANG, L., JIANG, J., WAQAS, M., IQBAL, M. & LI, J. 2018. Probiotic potential of *Leuconostoc pseudomesenteroides* and *Lactobacillus* strains isolated from yaks. *Front Microbiol*, 9.

WANG, Y. & MCALLISTER, T. A. 2002. Rumen microbes, enzymes and feed digestion-a review. *Asian-Australas J Anim Sci*, 15, 1659-1676.

WANG, Z., ROBERTS, A. B., BUFFA, J. A., LEVISON, B. S., ZHU, W., ORG, E., GU, X., HUANG, Y., ZAMANIAN-DARYOUSH, M., CULLEY, M. K., DIDONATO, A. J., FU, X., HAZEN, J. E., KRAJCIK, D., DIDONATO, J. A., LUSIS, A. J. & HAZEN, S. L. 2015. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. *Cell*, 163, 1585-1595.

WARREN, F. J., FUKUMA, N. M., MIKKELSEN, D., FLANAGAN, B. M., WILLIAMS, B. A., LISLE, A. T., P. O. C., MORRISON, M. & GIDLEY, M. J. 2018. Food starch structure impacts gut microbiome composition. *mSphere*, 3.

XIA, S., XU, B., HUANG, L., ZHAO, J.-Y., RAN, L., ZHANG, J., CHEN, H., PULSRIKARN, C., PORNRUANGWONG, S., AARESTRUP, F. M. & HENDRIKSEN, R. S. 2011. Prevalence and characterization of human *Shigella* infections in Henan Province, China, in 2006. *J Clin Microbiol*, 49, 232-242.

YADAV, M., VERMA, M. K. & CHAUHAN, N. S. 2018. A review of metabolic potential of human gut microbiome in human nutrition. *Arch Microbiol*, 200, 203-217.

YAMAMOTO, D., HERNANDES, R. T., LIBERATORE, A. M. A., ABE, C. M., SOUZA, R. B. D., ROMÃO, F. T., SPERANDIO, V., KOH, I. H. & GOMES, T. A. T. 2017. *Escherichia albertii*, a novel human enteropathogen, colonizes rat enterocytes and translocates to extra-intestinal sites. *PLoS One*, 12, e0171385-e0171385.

YOSHII, K., HOSOMI, K., SAWANE, K. & KUNISAWA, J. 2019. Metabolism of dietary and microbial vitamin B family in the regulation of host immunity. *Front Nutr*, 6, 48.

YUE, S. J., LIU, J., WANG, A. T., MENG, X. T., YANG, Z. R., PENG, C., GUAN, H. S., WANG, C. Y. & YAN, D. 2019. Berberine alleviates insulin resistance by reducing peripheral branched-chain amino acids. *Am J Physiol Endocrinol Metab*, 316, E73-e85.

ZE, X., BEN DAVID, Y., LAVERDE-GOMEZ, J. A., DASSA, B., SHERIDAN, P. O., DUNCAN, S. H., LOUIS, P., HENRISSAT, B., JUGE, N., KOROPATKIN, N. M., BAYER, E. A. & FLINT, H. J. 2015. Unique organization of extracellular amylases into amyloosomes in the resistant starch-utilizing human colonic *Firmicutes* bacterium *Ruminococcus bromii*. *mBio*, 6, e01058-15.

ZE, X., DUNCAN, S. H., LOUIS, P. & FLINT, H. J. 2012. *Ruminococcus bromii* is a keystone species for the degradation of resistant starch in the human colon. *Isme j*, 6, 1535-43.

ZHANG, W., LIU, M. & DAI, X. 2013. Biological characteristics and probiotic effect of *Leuconostoc lactis* strain isolated from the intestine of black porgy fish. *Braz J Microbiol*, 44, 685-91.

ZWART, H. 2015. Human Genome Project: history and assessment. *International encyclopedia of the social & behavioral sciences*. National Institutes of Health-Human Microbiome Project, <https://commonfund.nih.gov/hmp>



**PsomaHealth Laboratory**

21351 Gentry Drive, Suite 125

Sterling, VA 20166

CLIA#: 49D2172599

[help@psomagen.com](mailto:help@psomagen.com)

<https://mysomagen.com>